PEAK6’s Niagen Bioscience NAGE Stock Holding History

PEAK6’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16,000	Closed	-$231K	–	3591
2025 Q2	$231K	Buy	+16,000	New	+$158K	﹤0.01%	2403

Other funds holding NAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PEAK6's NAGE Position: Q3 2025 in Review

PEAK6 sold out of Niagen Bioscience (NAGE) in Q3 2025, closing a stake of 3,414 shares — an estimated $49.2K sold.

PEAK6 first reported a position in NAGE in Q2 2025 and held it in 1 quarter. The position peaked at $49.2K in Q2 2025. 162 funds tracked by Wall St. Rank hold NAGE as of Q3 2025.

PEAK6 reported no remaining Niagen Bioscience position as of Q3 2025 after selling out during the quarter.
PEAK6 sold 3,414 Niagen Bioscience shares in Q3 2025, an estimated $49.2K.
PEAK6 first reported a position in Niagen Bioscience in Q2 2025 and held it in 1 quarter.
PEAK6's Niagen Bioscience position peaked at $49.2K in Q2 2025.
162 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2025.

Based on PEAK6's 13F filing for Q3 2025, filed 14 Nov 2025.